The Immune Property of ESC-MSCs Is Tuned in Inflammatory Microenvironment

来源 :2016年国际组织工程与再生医学学会亚太会议 | 被引量 : 0次 | 上传用户:wajohn
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
其他文献
Objective: Spontaneous isolated dissection of the superior mesenteric artery(SIDSMA)is increasingly detected recently.Conservative treatment is now recommended as first choice for uncomplicated SIDSMA
Objective: To investigate the individualized treatment options on patients with variceal bleeding caused by portal hypertension.Materials and Methods: From January 2009 to December 2015,a consecutive
Objective: The purpose of this study was to assess the characteristics of fenestration malformation in vertebrobasilar artery a8 revealed by magnetic resonance angiography image(MRA)studies.
Purpose: To evaluate selective embolization for management of post-traumatic priapism and colour Doppler sonography and MRI for the diagnosis of the causative lesion and for planning embolization.
Objective: To study the effect,clinical value and feasibility of jugular vein hepatic interior vena cava shunt(TIPS)for liver cirrhosis with portal hypertension and gastrointestinal bleeding.
Purpose:To study the feasibility and safety of the shunt for extrahepatic portal vein and the hepatic vein.
Purpose: To studied the digital subtraction angiographic(DSA)characteristics of giant hepatic hemangioma,and the effectiveness of transcatheter arterial embolization(TAE)alone for its treatment.
Objective: To investigate the feasibility of parametric color coding of digital subtraction angiography(Syngo iFlow)for hemodynamics assessment in patients with critical limb ischaemia in pre-and post
Objective: To evaluate the safety and efficacy of percutaneous endovascular reconstruction with endovascular stent placement for isolated spontaneous dissection of the superior mesenteric artery(SMAD)
背景:近年来,晚期非小细胞肺癌(NSCLC)患者的主要治疗手段是化疗,但传统化疗方案具有较多的毒副反应且较为严重。为优化治疗手段,肿瘤免疫治疗已逐步成为目前抗肿瘤治疗的重要研究方向。程序性细胞死亡受体1(PD-1)/程序性死亡受体1配体1(PD-L1)抑制剂可经过多种方式使T淋巴细胞起到对抗肿瘤的免疫作用,信迪利单抗为国产PD-1抑制剂,但目前关于该药治疗晚期NSCLC的研究尚不充足。目的:PD-